Vascular Biogenics (NASDAQ:VBLT) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13), Morningstar.com reports. Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.25 million.

Vascular Biogenics stock traded down $0.05 during midday trading on Wednesday, hitting $1.20. The stock had a trading volume of 24,360 shares, compared to its average volume of 106,199. The stock has a fifty day moving average of $1.30. The stock has a market capitalization of $45.21 million, a P/E ratio of -1.93 and a beta of -0.33. Vascular Biogenics has a 52-week low of $0.60 and a 52-week high of $1.90. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.05.

Institutional investors have recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC boosted its stake in Vascular Biogenics by 216.7% in the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 23,950 shares during the period. Menta Capital LLC bought a new position in Vascular Biogenics in the 1st quarter worth approximately $35,000. Finally, First Republic Investment Management Inc. boosted its stake in Vascular Biogenics by 7.4% in the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 10,000 shares during the period. 6.80% of the stock is owned by institutional investors.

Several equities research analysts have recently commented on VBLT shares. Chardan Capital reaffirmed a “hold” rating and set a $3.00 price target on shares of Vascular Biogenics in a research report on Tuesday. Zacks Investment Research lowered shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research report on Thursday, May 30th. CIBC started coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They set an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Vascular Biogenics in a research report on Thursday, May 16th. Finally, ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $2.38.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Article: Depreciation

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.